Agenus Q2 revenue rises on access and royalty income
AGEN•Key financial detail
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Operating Income | $11.30 mln |
Analyst coverage and valuation
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Agenus Inc is $22.00, about 182.8% above its August 5 closing price of $7.78
- The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 6 three months ago
Funding outlook and use of proceeds
Upfront financing is expected to support operations through Q3 2027; warrants may extend funding to 2031.
- The company said broader BOT+BAL access programs across more countries and institutions contributed $6.4 mln in Q2 pre-commercial product revenue
- Agenus said it implemented disciplined cost-management measures and prioritized resources for ROBBIN trial execution
Quarterly revenue rose on royalty and access income
Agenus Q2 revenue rose year over year, driven by higher royalty and access program revenue.
